Product was Sonoma Pharmaceuticals’s largest product and service line in fiscal 2026, bringing in $35.36M of $35.72M (99%).
| Product and Service | FY 2017 | FY 2018 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Product | $18.85M | $20.22M | $25.27M | $35.36M | |||||
| Service | $2.69M | $844.00K | — | — | |||||
| Shipping & Handling | $84.00K | $56.00K | $36.00K | $360.00K | |||||
| Total | $21.63M | $21.12M | $25.31M | $35.72M |
Sonoma Pharmaceuticals brought in $35.72M from its two product and service lines in fiscal 2026, the year ended March 31, 2026. That is less than the $39.06M it reports by geography, so these lines do not cover all of its revenue. Product was the largest at $35.36M (99.0%), ahead of Shipping & Handling at $360.00K (1.0%).
Sonoma Pharmaceuticals stopped reporting Service as a separate line after fiscal 2024, when it brought in $844.00K.
Europe was Sonoma Pharmaceuticals’s largest region in fiscal 2026, bringing in $13.81M of $39.06M (35%).
| Geography | FY 2014 | FY 2017 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|
| Europe | $8.10M | $9.56M | $11.05M | $13.81M | ||||
| Europe & Other | — | — | — | — | ||||
| United States | $6.86M | $6.12M | $5.22M | $11.35M | ||||
| Mexico | — | — | — | — | ||||
| Latin America | $4.77M | $3.45M | $5.92M | $4.75M | ||||
| Asia | $4.90M | $4.60M | $4.63M | $5.80M | ||||
| Rest Of The World | $1.92M | $1.74M | $1.75M | $3.36M | ||||
| Total | $26.54M | $25.47M | $28.58M | $39.06M |
Sonoma Pharmaceuticals brought in $39.06M from its five regions in fiscal 2026, the year ended March 31, 2026. That was up 36.7% from $28.58M in fiscal 2025. Europe was the largest at $13.81M (35.4%), ahead of United States at $11.35M (29.1%) and Asia at $5.80M (14.8%). The other two regions brought in $8.10M combined.
Compared with fiscal 2025, United States grew fastest, up 117.3% to $11.35M, while Latin America fell the most, down 19.9% to $4.75M. From fiscal 2023 to 2026, combined revenue from these regions grew from $26.54M to $39.06M, a compound annual growth rate of 13.7%. Europe's share of the total rose from 30.5% to 35.4%.
Human Care was Sonoma Pharmaceuticals’s largest segment in fiscal 2026, bringing in $35.36M of $39.06M (91%).
| Statement Business Segments | FY 2021 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|
| Human Care | $18.85M | $20.22M | $25.27M | $35.36M | |
| Animal Care | $5.00M | $4.41M | $3.31M | $3.70M | |
| Service & Royalty | $2.69M | $844.00K | — | — | |
| Total | $26.54M | $25.47M | $28.58M | $39.06M |
Sonoma Pharmaceuticals brought in $39.06M from its two segments in fiscal 2026, the year ended March 31, 2026. That was up 36.7% from $28.58M in fiscal 2025. Human Care was the largest at $35.36M (90.5%), ahead of Animal Care at $3.70M (9.5%).
Compared with fiscal 2025, Human Care grew 39.9% to $35.36M and Animal Care grew 11.8% to $3.70M.
Sonoma Pharmaceuticals stopped reporting Service & Royalty as a separate segment after fiscal 2024, when it brought in $844.00K.
Sonoma Pharmaceuticals (SNOA) reports its revenue by product and service, by geography and by statement business segments. In fiscal 2026, Product was its largest product and service line, bringing in $35.36M (99.0% of the total), followed by Shipping & Handling at $360.00K (1.0%).
Product was Sonoma Pharmaceuticals' largest product and service line in fiscal 2026, bringing in $35.36M, or 99.0% of the $35.72M total across its two product and service lines.
Europe was Sonoma Pharmaceuticals' largest region in fiscal 2026, bringing in $13.81M, or 35.4% of the $39.06M total across its five regions.
Human Care was Sonoma Pharmaceuticals' largest segment in fiscal 2026, bringing in $35.36M, or 90.5% of the $39.06M total across its two segments.
Among Sonoma Pharmaceuticals' regions that make up at least 2% of revenue, United States grew fastest in fiscal 2026, up 117.3% from $5.22M to $11.35M.
Every figure comes from Sonoma Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Sonoma Pharmaceuticals gives it, and years follow its fiscal calendar.
Sonoma Pharmaceuticals' revenue by product and service goes back to fiscal 2017, with figures through fiscal 2026. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.